Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 19, 2024
- Alpha DaRT® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market access to the Alpha DaRT® for patients with recurrent glioblastoma multiforme (GBM) -
Read more at globenewswire.comNASDAQ:DRTSW (6/26/2025, 1:48:19 PM)
0.2498
0 (-0.04%)
NASDAQ:DRTS (6/26/2025, 2:06:32 PM)
3.07
+0.07 (+2.33%)
Find more stocks in the Stock Screener
